Vancouver’s Aspect Biosystems has announced the closing of an oversubscribed seed round funded by the local Vancouver Angel community.
Aspect is a world leader in the development of cutting edge 3D bioprinting technology capable of generating functional living human tissues.
Aspect has a vision of enabling human tissues on demand for a range of applications including pre-clinical drug discovery, basic research, cosmetic testing and personalized medicine.
“We are very impressed with Aspect’s breakthrough approach to 3D bioprinting and we believe that the company holds great potential for delivering highly advanced structured tissues in the near term,” Todd Farrell, President, [email protected] Seed Fund.
The financing will support the development of next generation 3D bioprinting technology and commercialization of Aspect’s first custom human tissue services and products.
“We deeply appreciate the support of Vancouver’s Angel investors who moved quickly to subscribe to this financing and we are very excited to take these key steps toward realizing Aspect Biosystems’ bold vision,” Konrad Walus, CEO.
Founded in 2013, Aspect was spun out from the University of British Columbia and based on advanced research conducted by an interdisciplinary team of world-class researchers in engineering and medicine.